Filter Results:
(1,248)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
Stanford, in addition to his Harvard MBA, Blum’s credentials make him well suited to a career in biotech. Prior to joining Cytokinetics, he had experience in sales, marketing, and business development in large and small pharmaceutical... View Details
Keywords: Deborah Blagg
- 10 Jun 2021
- Blog Post
Managing Sustainable Advantage with Key ESG Cofounders, Anne-Marie Schoonbeek and Heleen van Poecke
internship and then later back to McKinsey after graduation, where she focused on both large-cap and startups in the pharmaceuticals and biotech space. “For me, this was a way of making an impact,” said Schoonbeek. van Poecke began her... View Details
- 19 Dec 2005
- Research & Ideas
The Regional Slice of Your Global Strategy
equipment, and pharmaceuticals have invested significantly in modern mapping technology, using such innovations as enhanced clustering techniques, better measures for analyzing networks, and expanded data on bilateral, multilateral, and... View Details
Keywords: by Pankaj Ghemawat
- 09 Jan 2007
- First Look
First Look: January 9, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707413 Teva Pharmaceutical Industries, Ltd. Harvard Business School Case 707-441 Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707441 ... View Details
Keywords: Martha Lagace
- July 2017 (Revised July 2019)
- Supplement
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B)
By: Nori Gerardo Lietz and Ricardo Andrade
The B Case of "Dr. My Eyes" provides the answer as to what happened after the ending fact pattern in Case A and the imminent choices faced by the protagonist in the primary case. At the end of the Case A, Bess Weatherman of Warburg Pincus, must chose one option of two... View Details
Keywords: Private Equity; Health Care and Treatment; Mergers and Acquisitions; Corporate Governance; Decision Choices and Conditions; Outcome or Result; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lietz, Nori Gerardo, and Ricardo Andrade. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B). Harvard Business School Supplement 218-029, July 2017. (Revised July 2019.)
- July 2016 (Revised July 2019)
- Teaching Plan
Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)
By: Nori Gerardo Lietz and Ricardo Andrade
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
- April 2016 (Revised July 2019)
- Case
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)
- August 2003
- Teaching Note
Pharmacyclics: Financing Research and Development (TN)
By: Malcolm P. Baker and Richard S. Ruback
Teaching Note for (9-201-056). View Details
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
- 01 Aug 2001
- News
Cleveland Global Alumni Conference a Sold-Out Success
& Co., kicked off the first plenary session with a quick overview of factors contributing to the U.S. pharmaceutical industry's success in competing in the global market. Among other ad- vantages, Gilmartin cited the U.S. government's... View Details
- March 2015
- Teaching Note
CVS Health: Promoting Drug Adherence
Email mking@hbs.edu for a courtesy copy.
This Teaching Note explains the theory of the case and teaching plan for the case: CVS Health: Promoting Drug Adherence (515010). The case finds Helena Foulkes, Executive... View Details
This Teaching Note explains the theory of the case and teaching plan for the case: CVS Health: Promoting Drug Adherence (515010). The case finds Helena Foulkes, Executive... View Details
Keywords: Medication Adherence; Affordable Care Act (ACA); Marketing Strategy; Communication Strategy; Customer Value and Value Chain; Decisions; Health Care and Treatment; Goals and Objectives; Resource Allocation; Marketing Communications; Consumer Behavior; Measurement and Metrics; Service Delivery; Behavior; Motivation and Incentives; Social Issues; Information Technology; Value Creation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
John, Leslie, John Quelch, and Robert Huckman. "CVS Health: Promoting Drug Adherence." Harvard Business School Teaching Note 515-086, March 2015. (Email mking@hbs.edu for a courtesy copy.)
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants,... View Details
Keywords: Sean Silverthorne
- 05 Aug 2014
- First Look
First Look: August 5
Case 614-063 Merrimack Pharmaceuticals, Inc. (A) In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition... View Details
Keywords: Sean Silverthorne
- February 1985 (Revised July 1993)
- Case
Puritan Drug Co.
David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of a case by R.Z. Sorenson. View Details
Keywords: Salesforce Management; Conflict and Resolution; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Moriarty, Rowland T., Jr. "Puritan Drug Co." Harvard Business School Case 585-158, February 1985. (Revised July 1993.)
- 03 Feb 2015
- First Look
First Look: February 3
architecture, including business- and technology-related aspects. We apply our methodology to data gathered in a large pharmaceutical firm. We show that this methodology helps to identify layers in the firm's architecture associated with... View Details
Keywords: Sean Silverthorne
- 30 Jun 2003
- Research & Ideas
Computer Security is For Managers, Too
each warrants. A bank, for instance, might assign the greatest amount of protection to the database that stores its customers' financial information. For a pharmaceutical company, it might be the research servers that hold data on... View Details
- May 2025 (Revised May 2025)
- Supplement
Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)
By: Linda A. Hill and Lydia Begag
This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details
- April 2025
- Case
Radical Transformation at Bayer: Dynamic Shared Ownership
By: Boris Groysberg and Gamze Yucaoglu
In 2023, Bill Anderson became CEO of Bayer AG, a 160-year-old life sciences giant looking to strengthen its pharma pipeline, manage debt, and cut through bureaucracy. His bold response: Dynamic Shared Ownership (DSO), a radical model replacing traditional hierarchies... View Details
Keywords: Human Resources; Business Strategy; Alignment; Innovation and Management; Organizational Structure; Pharmaceutical Industry; Pharmaceutical Industry
Groysberg, Boris, and Gamze Yucaoglu. "Radical Transformation at Bayer: Dynamic Shared Ownership." Harvard Business School Case 425-061, April 2025.
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- 2014
- Working Paper
Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms
By: Prithwiraj Choudhury and Tarun Khanna
Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details
Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry
Choudhury, Prithwiraj, and Tarun Khanna. "Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms." Harvard Business School Working Paper, No. 14-081, February 2014.